Table 1 Demographic and baseline disease characteristics.

From: Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer

 

1 × 108 CFU n = 6

1 × 109 CFU n = 20

Total n = 26

Median age, years (range)

74 (58–77)

65 (46–85)

67 (46–85)

Race, n (%)

  White

5 (83)

20 (100)

25 (96)

  Black or African American

1 (17)

0

1 (4)

ECOG PS, n (%)

  0

2 (33)

7 (35)

9 (35)

  1

4 (67)

13 (65)

17 (65)

Time from initial diagnosis, years (range)

5 (1–18)

6 (1–17)

6 (1–18)

Gleason score, n (%)

  <7

1 (17)

2 (10)

3 (12)

  7

2 (33)

3 (15)

5 (19)

  ≥8

3 (50)

13 (65)

16 (62)

  Unknown

0

2 (10)

2 (8)

Extent of disease at entry, n (%)

  Bone

4 (67)

19 (95)

23 (89)

  Bone only

1 (17)

6 (30)

7 (27)

  Soft tissue or node

2 (33)

14 (70)

16 (62)

  Other

3 (50)

5 (25)

8 (31)

Evidence of disease progression, n (%)

  PSA

0

14 (74)

14 (56)

  Radiographic

6 (100)

11 (58)

17 (68)

Laboratory parameters

  Median hemoglobin, g/dL (range)

10 (9–13)

11 (9–14)

11 (9–14)

  Median alkaline phosphatase, U/L (range)

178 (74–633)

88 (25–1015)

96 (25–1015)

  Median lactate dehydrogenase, U/L (range)

849 (314–2719)

370 (99–2203)

401 (99–2719)

  1. CFU colony-forming unit, ECOG PS Eastern Cooperative Oncology Group performance status, PSA prostate-specific antigen.